Inactive Instrument

Lonza Group Ltd Stock Other OTC

Equities

LZAGY

US54338V1017

Biotechnology & Medical Research

Financials

Sales 2024 * 6.64B 7.27B 9.92B Sales 2025 * 7.44B 8.15B 11.12B Capitalization 38.06B 41.68B 56.85B
Net income 2024 * 904M 990M 1.35B Net income 2025 * 1.11B 1.22B 1.66B EV / Sales 2024 * 6.06 x
Net Debt 2024 * 2.18B 2.38B 3.25B Net Debt 2025 * 2.47B 2.7B 3.69B EV / Sales 2025 * 5.44 x
P/E ratio 2024 *
42.7 x
P/E ratio 2025 *
34.2 x
Employees -
Yield 2024 *
0.85%
Yield 2025 *
0.98%
Free-Float 95.87%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Lonza Group Ltd

Managers TitleAgeSince
Chief Executive Officer 72 17-04-24
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company